… Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced
EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with …

… Patients and Methods In this randomized, cross-over, pharmacokinetic study in patients with
non–small-cell lung cancer… day period of concomitant treatment with erlotinib, with or without …

… erlotinib would be safe and show efficacy in patients with EGFR-mutated tumors experiencing
disease progression on erlotinib … patients with EGFR WT tumors with MET dysregulation. …

… cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not
widely implemented. RELAY assessed erlotinib… or placebo in patients with untreated EGFR…

… (TKI) erlotinib has been at the forefront of changes in treatment practice for advanced non–small
cell lung cancer (NSCLC) over the past 10 years. Erlotinib was initially approved for use …

… The MTD of the combination of crizotinib and erlotinib in patients with advanced NSCLC
was crizotinib, 150 mg twice daily, with erlotinib, 100 mg once daily, which is less than the …

… nonsmall-cell lung cancer (NSCLC), dacomitinib showed improved PFS compared with
erlotinib in … This led to a phase III study of dacomitinib versus erlotinib in patients with advanced …

… 10 or fewer patients in the database, and no patients were identified with use of afatinib or
ceritinib. Therefore, this analysis was limited to patients who received erlotinib. Erlotinib was …

… Tumor genotyping has emerged as the standard of care for patients with newly diagnosed
non–small cell lung cancer (NSCLC) because of the efficacy of targeted therapies for patients …

… of seribantumab plus erlotinib in advanced non‐small cell lung cancer (NSCLC). Here, we
report the activity of seribantumab plus erlotinib, versus erlotinib alone, in patients with EGFR …